메뉴 건너뛰기




Volumn 25, Issue 12, 2011, Pages 1481-1487

A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study)

Author keywords

cross over; efavirenz; neuropsychiatric side effects; preference; raltegravir

Indexed keywords

CHOLESTEROL; EFAVIRENZ; LOW DENSITY LIPOPROTEIN; RALTEGRAVIR; TRIACYLGLYCEROL; VIRUS RNA;

EID: 79960563547     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328348dab0     Document Type: Article
Times cited : (62)

References (30)
  • 1
    • 0033576816 scopus 로고    scopus 로고
    • Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
    • Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults.N Engl J Med 1999; 341:1865-1873.
    • (1999) N Engl J Med , vol.341 , pp. 1865-1873
    • Staszewski, S.1    Morales-Ramirez, J.2    Tashima, K.T.3    Rachlis, A.4    Skiest, D.5    Stanford, J.6
  • 2
    • 84875886913 scopus 로고    scopus 로고
    • Accessed 7 April 2010
    • DHHS guidelines. http://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail. aspx?GuidelineID&7 [Accessed 7 April 2010].
    • DHHS Guidelines
  • 3
    • 84856071427 scopus 로고    scopus 로고
    • Accessed 7 April 2010
    • EACS recommendations. http://www.europeanaidsclinicalsociety.org/ guidelines.asp [Accessed 7 April 2010].
    • EACS Recommendations
  • 4
    • 0007895376 scopus 로고    scopus 로고
    • DuPont Pharmaceuticals Efavirenz: DuPont Pharmaceuticals
    • DuPont Pharmaceuticals. Product Information Sustiva. Efavirenz: DuPont Pharmaceuticals; 1998.
    • (1998) Product Information Sustiva
  • 6
    • 0032441604 scopus 로고    scopus 로고
    • Efavirenz
    • Adkins JC, Nobles S. Efavirenz. Drugs 1998; 56:1055-1066.
    • (1998) Drugs , vol.56 , pp. 1055-1066
    • Adkins, J.C.1    Nobles, S.2
  • 7
    • 28144452516 scopus 로고    scopus 로고
    • Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals
    • Clifford DB, Evans S, Yang Y, Acosta EP, Goodkin K, Tashima K, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005; 143:714-721.
    • (2005) Ann Intern Med , vol.143 , pp. 714-721
    • Clifford, D.B.1    Evans, S.2    Yang, Y.3    Acosta, E.P.4    Goodkin, K.5    Tashima, K.6
  • 10
    • 35348995999 scopus 로고    scopus 로고
    • Is it safe to switch between efavirenz and nevirapine in the event of toxicity?
    • DOI 10.1016/S1473-3099(07)70262-1, PII S1473309907702621
    • Mehta U, Maartens G. Is it safe to switch between efavirenz and nevirapine in the event of toxicity? Lancet Infect Dis 2007; 7:733-738. (Pubitemid 47600092)
    • (2007) Lancet Infectious Diseases , vol.7 , Issue.11 , pp. 733-738
    • Mehta, U.1    Maartens, G.2
  • 11
    • 34347348060 scopus 로고    scopus 로고
    • No patient left behind-better treatments for resistant HIV infection
    • DOI 10.1016/S0140-6736(07)61022-8, PII S0140673607610228
    • Hirschel B, Perneger T. No patient left behind: better treatments for resistant HIV infection. Lancet 2007; 370:3-5. (Pubitemid 47017448)
    • (2007) Lancet , vol.370 , Issue.9581 , pp. 3-5
    • Hirschel, B.1    Perneger, T.2
  • 12
    • 75149175071 scopus 로고    scopus 로고
    • Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): Two multicentre, double-blind, randomised controlled trials
    • for the SWITCHMRK 1 and 2 investigators
    • Eron JJ, Young B, Cooper DA, Youle M, Dejesus E, Andrade-Villanueva J, et al.; for the SWITCHMRK 1 and 2 investigators. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375:396-407.
    • (2010) Lancet , vol.375 , pp. 396-407
    • Eron, J.J.1    Young, B.2    Cooper, D.A.3    Youle, M.4    Dejesus, E.5    Andrade-Villanueva, J.6
  • 13
    • 78650306222 scopus 로고    scopus 로고
    • A randomized crossover study to compare efavirenz and etravirine treatment
    • Swiss HIV Cohort Study
    • Nguyen A, Calmy A, Delhumeau C, Mercier IK, Cavassini M, Fayet-Mello A, Elzi L, Swiss HIV Cohort Study. A randomized crossover study to compare efavirenz and etravirine treatment. AIDS 2011; 25:57-63.
    • (2011) AIDS , vol.25 , pp. 57-63
    • Nguyen, A.1    Calmy, A.2    Delhumeau, C.3    Mercier, I.K.4    Cavassini, M.5    Fayet-Mello, A.6    Elzi, L.7
  • 14
    • 17144385842 scopus 로고    scopus 로고
    • Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry
    • DOI 10.1016/j.jchromb.2005.02.010
    • Colombo S, Beguin A, Telenti A, Biollaz J, Buclin T, Rochat B, et al. Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 819:259-276. (Pubitemid 40521961)
    • (2005) Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences , vol.819 , Issue.2 , pp. 259-276
    • Colombo, S.1    Beguin, A.2    Telenti, A.3    Biollaz, J.4    Buclin, T.5    Rochat, B.6    Decosterd, L.A.7
  • 15
    • 58149134503 scopus 로고    scopus 로고
    • Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction
    • Fayet A, Béguin A, de Tejada BM, Colombo S, Cavassini M, Gerber S, et al. Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction. Ther Drug Monit 2008; 30:511-522.
    • (2008) Ther Drug Monit , vol.30 , pp. 511-522
    • Fayet, A.1    Béguin, A.2    De Tejada, B.M.3    Colombo, S.4    Cavassini, M.5    Gerber, S.6
  • 16
    • 63249093621 scopus 로고    scopus 로고
    • A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine
    • Fayet A, Béguin A, Zanolari B, Cruchon S, Guignard N, Telenti A, et al. A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: raltegravir, maraviroc, darunavir, and etravirine. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877:1057-1069.
    • (2009) J Chromatogr B Analyt Technol Biomed Life Sci , vol.877 , pp. 1057-1069
    • Fayet, A.1    Béguin, A.2    Zanolari, B.3    Cruchon, S.4    Guignard, N.5    Telenti, A.6
  • 17
    • 0003586930 scopus 로고
    • Manual for the Depression Anxiety Stress Scales (DASS) Sydney, Australia: University of New South Wales
    • Lovibond SH, Lovibond PF. Manual for the Depression Anxiety Stress Scales (DASS). Psychology Foundation Monograph. Sydney, Australia: University of New South Wales; 1993.
    • (1993) Psychology Foundation Monograph
    • Lovibond, S.H.1    Lovibond, P.F.2
  • 18
    • 0031021390 scopus 로고    scopus 로고
    • Psychometric properties of the Depression Anxiety Stress Scales (DASS) in clinical samples
    • DOI 10.1016/S0005-7967(96)00068-X
    • Brown TA, Chorpita BF, Korotitsch W, Barlow DH. Psychometric properties of the Depression Anxiety Stress Scales (DASS) in clinical samples. Behav Res Ther 1997; 1:79-89. (Pubitemid 27026171)
    • (1997) Behaviour Research and Therapy , vol.35 , Issue.1 , pp. 79-89
    • Brown, T.A.1    Chorpita, B.F.2    Korotitsch, W.3    Barlow, D.H.4
  • 19
    • 0026333617 scopus 로고
    • A new method for measuring daytime sleepiness: The Epworth sleepiness scale
    • Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14:540-545.
    • (1991) Sleep , vol.14 , pp. 540-545
    • Johns, M.W.1
  • 22
    • 33748340844 scopus 로고    scopus 로고
    • Validation of the revised 10-item HIV treatment satisfaction questionnaire status version and new change version
    • DOI 10.1111/j.1524-4733.2006.00121.x
    • Woodcock A, Bradley C. Validation of the Revised 10-Item HIV Treatment Satisfaction Questionnaire Status Version and New Change Version. Value Health 2006; 9:320-333. (Pubitemid 44337785)
    • (2006) Value in Health , vol.9 , Issue.5 , pp. 320-333
    • Woodcock, A.1    Bradley, C.2
  • 25
    • 0035875828 scopus 로고    scopus 로고
    • Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
    • DOI 10.1097/00002030-200101050-00011
    • Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients. AIDS 2001; 15:71-75. (Pubitemid 32055781)
    • (2001) AIDS , vol.15 , Issue.1 , pp. 71-75
    • Marzolini, C.1    Telenti, A.2    Decosterd, L.A.3    Greub, G.4    Biollaz, J.5    Buclin, T.6
  • 26
    • 28044459173 scopus 로고    scopus 로고
    • Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring
    • DOI 10.1086/497835
    • Gutiérrez F, Navarro A, Padilla S, Antón R, Masiá M, Borrás J, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 2005; 41:1648-1653. (Pubitemid 41691605)
    • (2005) Clinical Infectious Diseases , vol.41 , Issue.11 , pp. 1648-1653
    • Gutierrez, F.1    Navarro, A.2    Padilla, S.3    Anton, R.4    Masia, M.5    Borras, J.6    Martin-Hidalgo, A.7
  • 27
    • 67649236216 scopus 로고    scopus 로고
    • The nucleoside backbone affects durability of efavirenz-or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals
    • Annan NT, Nelson M, Mandalia S, Bower M, Gazzard BG, Stebbing J. The nucleoside backbone affects durability of efavirenz-or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals. J Acquir Immune Defic Syndr 2009; 51:140-146.
    • (2009) J Acquir Immune Defic Syndr , vol.51 , pp. 140-146
    • Annan, N.T.1    Nelson, M.2    Mandalia, S.3    Bower, M.4    Gazzard, B.G.5    Stebbing, J.6
  • 29
    • 47949120697 scopus 로고    scopus 로고
    • Raltegravir with optimized background therapy for resistant HIV-1 infection
    • BENCHMRK Study Teams
    • Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al., BENCHMRK Study Teams. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354.
    • (2008) N Engl J Med , vol.359 , pp. 339-354
    • Steigbigel, R.T.1    Cooper, D.A.2    Kumar, P.N.3    Eron, J.E.4    Schechter, M.5    Markowitz, M.6
  • 30
    • 77954348583 scopus 로고    scopus 로고
    • Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: The SPIRAL study
    • SPIRAL Study Group
    • Mart́nez E, Larrousse M, Llibre JM, Gutiérrez F, Saumoy M, Antela A, et al., SPIRAL Study Group. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010; 24:1697-1707.
    • (2010) AIDS , vol.24 , pp. 1697-1707
    • Mart́nez, E.1    Larrousse, M.2    Llibre, J.M.3    Gutiérrez, F.4    Saumoy, M.5    Antela, A.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.